Identification and Evaluation of a Highly Effective Fusion Inhibitor for Human Metapneumovirus
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...
Saved in:
| Published in | Antimicrobial Agents and Chemotherapy Vol. 52; no. 1; pp. 279 - 287 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.01.2008
American Society for Microbiology (ASM) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
|
|---|---|
| AbstractList | Human metapneumovirus (hMPV) can cause acute upper and lower respiratory tract infections that are particularly severe in young children, elderly subjects, and immunocompromised patients. To date, no treatments or vaccines are available for hMPV infections. Our objective was to assess the inhibitory potential of several peptides derived from the heptad repeat A and B (HRA and HRB) domains of the hMPV fusion protein. Nine candidate peptides were expressed in
Escherichia coli
or obtained synthetically and tested in vitro and in an animal model. Excellent in vitro inhibition of an hMPV strain of the A1 subgroup was obtained with five peptides, with 50% inhibitory concentrations ranging from 1.4 nM to 3.3 μM. One peptide, HRA2, displayed very potent activity against all four hMPV subgroups. It was also moderately active against human respiratory syncytial virus (strain A2) but displayed no activity against human parainfluenza virus type 3. BALB/c mice that received the HRA2 peptide and a lethal hMPV intranasal challenge simultaneously were completely protected from clinical symptoms and mortality. On day 5 postinfection, HRA2-treated mice had undetectable lung viral loads which were significantly less than those of untreated mice (3 × 10
4
50% tissue culture infective doses/lung). Pulmonary inflammation, levels of proinflammatory cytokines/chemokines (RANTES, gamma interferon, and monocyte chemoattractant protein 1) and airway obstruction were also significantly decreased in HRA2-treated mice. The results of this study demonstrate that potent antivirals can be derived from the hMPV fusion protein HR domains. Moreover, hMPV, compared to other paramyxoviruses and to the human immunodeficiency virus, seems to be more susceptible to HRA- than HRB-derived peptides. Human metapneumovirus (hMPV) can cause acute upper and lower respiratory tract infections that are particularly severe in young children, elderly subjects, and immunocompromised patients. To date, no treatments or vaccines are available for hMPV infections. Our objective was to assess the inhibitory potential of several peptides derived from the heptad repeat A and B (HRA and HRB) domains of the hMPV fusion protein. Nine candidate peptides were expressed in Escherichia coli or obtained synthetically and tested in vitro and in an animal model. Excellent in vitro inhibition of an hMPV strain of the A1 subgroup was obtained with five peptides, with 50% inhibitory concentrations ranging from 1.4 nM to 3.3 microM. One peptide, HRA2, displayed very potent activity against all four hMPV subgroups. It was also moderately active against human respiratory syncytial virus (strain A2) but displayed no activity against human parainfluenza virus type 3. BALB/c mice that received the HRA2 peptide and a lethal hMPV intranasal challenge simultaneously were completely protected from clinical symptoms and mortality. On day 5 postinfection, HRA2-treated mice had undetectable lung viral loads which were significantly less than those of untreated mice (3 x 10(4) 50% tissue culture infective doses/lung). Pulmonary inflammation, levels of proinflammatory cytokines/chemokines (RANTES, gamma interferon, and monocyte chemoattractant protein 1) and airway obstruction were also significantly decreased in HRA2-treated mice. The results of this study demonstrate that potent antivirals can be derived from the hMPV fusion protein HR domains. Moreover, hMPV, compared to other paramyxoviruses and to the human immunodeficiency virus, seems to be more susceptible to HRA- than HRB-derived peptides. Human metapneumovirus (hMPV) can cause acute upper and lower respiratory tract infections that are particularly severe in young children, elderly subjects, and immunocompromised patients. To date, no treatments or vaccines are available for hMPV infections. Our objective was to assess the inhibitory potential of several peptides derived from the heptad repeat A and B (HRA and HRB) domains of the hMPV fusion protein. Nine candidate peptides were expressed in Escherichia coli or obtained synthetically and tested in vitro and in an animal model. Excellent in vitro inhibition of an hMPV strain of the A1 subgroup was obtained with five peptides, with 50% inhibitory concentrations ranging from 1.4 nM to 3.3 microM. One peptide, HRA2, displayed very potent activity against all four hMPV subgroups. It was also moderately active against human respiratory syncytial virus (strain A2) but displayed no activity against human parainfluenza virus type 3. BALB/c mice that received the HRA2 peptide and a lethal hMPV intranasal challenge simultaneously were completely protected from clinical symptoms and mortality. On day 5 postinfection, HRA2-treated mice had undetectable lung viral loads which were significantly less than those of untreated mice (3 x 10(4) 50% tissue culture infective doses/lung). Pulmonary inflammation, levels of proinflammatory cytokines/chemokines (RANTES, gamma interferon, and monocyte chemoattractant protein 1) and airway obstruction were also significantly decreased in HRA2-treated mice. The results of this study demonstrate that potent antivirals can be derived from the hMPV fusion protein HR domains. Moreover, hMPV, compared to other paramyxoviruses and to the human immunodeficiency virus, seems to be more susceptible to HRA- than HRB-derived peptides.Human metapneumovirus (hMPV) can cause acute upper and lower respiratory tract infections that are particularly severe in young children, elderly subjects, and immunocompromised patients. To date, no treatments or vaccines are available for hMPV infections. Our objective was to assess the inhibitory potential of several peptides derived from the heptad repeat A and B (HRA and HRB) domains of the hMPV fusion protein. Nine candidate peptides were expressed in Escherichia coli or obtained synthetically and tested in vitro and in an animal model. Excellent in vitro inhibition of an hMPV strain of the A1 subgroup was obtained with five peptides, with 50% inhibitory concentrations ranging from 1.4 nM to 3.3 microM. One peptide, HRA2, displayed very potent activity against all four hMPV subgroups. It was also moderately active against human respiratory syncytial virus (strain A2) but displayed no activity against human parainfluenza virus type 3. BALB/c mice that received the HRA2 peptide and a lethal hMPV intranasal challenge simultaneously were completely protected from clinical symptoms and mortality. On day 5 postinfection, HRA2-treated mice had undetectable lung viral loads which were significantly less than those of untreated mice (3 x 10(4) 50% tissue culture infective doses/lung). Pulmonary inflammation, levels of proinflammatory cytokines/chemokines (RANTES, gamma interferon, and monocyte chemoattractant protein 1) and airway obstruction were also significantly decreased in HRA2-treated mice. The results of this study demonstrate that potent antivirals can be derived from the hMPV fusion protein HR domains. Moreover, hMPV, compared to other paramyxoviruses and to the human immunodeficiency virus, seems to be more susceptible to HRA- than HRB-derived peptides. Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology. For an alternate route to AAC .asm.org, visit: AAC Human metapneumovirus (hMPV) can cause acute upper and lower respiratory tract infections that are particularly severe in young children, elderly subjects, and immunocompromised patients. To date, no treatments or vaccines are available for hMPV infections. Our objective was to assess the inhibitory potential of several peptides derived from the heptad repeat A and B (HRA and HRB) domains of the hMPV fusion protein. Nine candidate peptides were expressed in Escherichia coli or obtained synthetically and tested in vitro and in an animal model. Excellent in vitro inhibition of an hMPV strain of the A1 subgroup was obtained with five peptides, with 50% inhibitory concentrations ranging from 1.4 nM to 3.3 μM. One peptide, HRA2, displayed very potent activity against all four hMPV subgroups. It was also moderately active against human respiratory syncytial virus (strain A2) but displayed no activity against human parainfluenza virus type 3. BALB/c mice that received the HRA2 peptide and a lethal hMPV intranasal challenge simultaneously were completely protected from clinical symptoms and mortality. On day 5 postinfection, HRA2-treated mice had undetectable lung viral loads which were significantly less than those of untreated mice (3 × 104 50% tissue culture infective doses/lung). Pulmonary inflammation, levels of proinflammatory cytokines/chemokines (RANTES, gamma interferon, and monocyte chemoattractant protein 1) and airway obstruction were also significantly decreased in HRA2-treated mice. The results of this study demonstrate that potent antivirals can be derived from the hMPV fusion protein HR domains. Moreover, hMPV, compared to other paramyxoviruses and to the human immunodeficiency virus, seems to be more susceptible to HRA- than HRB-derived peptides. Human metapneumovirus (hMPV) can cause acute upper and lower respiratory tract infections that are particularly severe in young children, elderly subjects, and immunocompromised patients. To date, no treatments or vaccines are available for hMPV infections. Our objective was to assess the inhibitory potential of several peptides derived from the heptad repeat A and B (HRA and HRB) domains of the hMPV fusion protein. Nine candidate peptides were expressed in Escherichia coli or obtained synthetically and tested in vitro and in an animal model. Excellent in vitro inhibition of an hMPV strain of the A1 subgroup was obtained with five peptides, with 50% inhibitory concentrations ranging from 1.4 nM to 3.3 mu M. One peptide, HRA2, displayed very potent activity against all four hMPV subgroups. It was also moderately active against human respiratory syncytial virus (strain A2) but displayed no activity against human parainfluenza virus type 3. BALB/c mice that received the HRA2 peptide and a lethal hMPV intranasal challenge simultaneously were completely protected from clinical symptoms and mortality. On day 5 postinfection, HRA2-treated mice had undetectable lung viral loads which were significantly less than those of untreated mice (3 x 10 super(4) 50% tissue culture infective doses/lung). Pulmonary inflammation, levels of proinflammatory cytokines/chemokines (RANTES, gamma interferon, and monocyte chemoattractant protein 1) and airway obstruction were also significantly decreased in HRA2-treated mice. The results of this study demonstrate that potent antivirals can be derived from the hMPV fusion protein HR domains. Moreover, hMPV, compared to other paramyxoviruses and to the human immunodeficiency virus, seems to be more susceptible to HRA- than HRB-derived peptides. |
| Author | Marie-Ève Hamelin Céline Deffrasnes Guy Boivin Gregory A. Prince |
| AuthorAffiliation | Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada, 1 Virion Systems, Inc., Rockville, Maryland 2 |
| AuthorAffiliation_xml | – name: Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada, 1 Virion Systems, Inc., Rockville, Maryland 2 |
| Author_xml | – sequence: 1 givenname: Céline surname: Deffrasnes fullname: Deffrasnes, Céline organization: Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada – sequence: 2 givenname: Marie-Ève surname: Hamelin fullname: Hamelin, Marie-Ève organization: Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada – sequence: 3 givenname: Gregory A. surname: Prince fullname: Prince, Gregory A. organization: Virion Systems, Inc., Rockville, Maryland – sequence: 4 givenname: Guy surname: Boivin fullname: Boivin, Guy organization: Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20210384$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17967906$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk1vEzEQhi1URNPCjTPaC0hI3WJ7118XpChKSaQiLj1jef3RuNq1g70b1H-P04QWEIiDbY3m8euZeX0GTkIMFoDXCF4ihPmH-XxxCSETTQ3ZMzBDUPCaEkFPwAxCSuuWw_YUnOV8B0tMBHwBThETlAlIZ-Dr2tgweue1Gn0MlQqmWu5UPx3C6CpVrfztpr-vls5ZPfqdra6mvE-uw8Z3foypcmWtpkGF6rMd1TbYaYg7n6b8Ejx3qs_21fE8BzdXy5vFqr7-8mm9mF_XqqXtWGNuSNsY4ojrYGcwaSzhqjHGaeosZ6JslOGOWqMYscZYrqlG2glCiDHNOfh4kN1O3WCNLi0l1ctt8oNK9zIqL3_PBL-Rt3EnMcYN57AIvDsKpPhtsnmUg8_a9r0KNk5ZMogYZJz9F0RCcC4YL-D7A6jygOVdnFIoA5AIyr1rsrgmH1yTcC_65tfyH-v-aVMB3h4BlbXqXVJB-_zIYYgRbHhbuIsDp1PMOVn3JPX3d_EfuPbjg_FlSL7_16XqcGlTvsV3n6wsHUqltCRYIokL9gO6m8z3 |
| CODEN | AACHAX |
| CitedBy_id | crossref_primary_10_3389_fmed_2021_575580 crossref_primary_10_1007_s00425_015_2277_5 crossref_primary_10_1016_j_jviromet_2018_05_012 crossref_primary_10_1007_s13312_013_0265_z crossref_primary_10_1099_jgv_0_001135 crossref_primary_10_3390_v14020395 crossref_primary_10_1186_1743_422X_6_138 crossref_primary_10_1128_CMR_00039_14 crossref_primary_10_1111_bph_14084 crossref_primary_10_1097_MRM_0b013e3283530823 crossref_primary_10_1080_21505594_2016_1265725 crossref_primary_10_1007_s40124_014_0048_6 crossref_primary_10_1128_JVI_02198_08 crossref_primary_10_1016_j_ijid_2014_03_1394 crossref_primary_10_3390_v5010087 crossref_primary_10_1016_j_virusres_2015_02_024 crossref_primary_10_1177_135965350801300603 crossref_primary_10_1089_vim_2020_0018 crossref_primary_10_1002_rmv_1717 crossref_primary_10_1007_s13337_018_0498_5 crossref_primary_10_1080_14760584_2017_1283223 crossref_primary_10_3390_pathogens9020109 crossref_primary_10_3390_v5010192 crossref_primary_10_1128_JVI_05485_11 crossref_primary_10_1111_bjh_14027 crossref_primary_10_1016_j_jcv_2013_08_029 crossref_primary_10_1016_j_antiviral_2022_105405 crossref_primary_10_1203_PDR_0b013e31819db90c crossref_primary_10_1371_journal_ppat_1007689 crossref_primary_10_1099_jgv_0_000796 crossref_primary_10_1155_2013_595768 crossref_primary_10_1093_infdis_jis333 crossref_primary_10_1002_rmv_651 crossref_primary_10_1016_j_virusres_2011_06_014 crossref_primary_10_1371_journal_pone_0120283 crossref_primary_10_1016_j_jcv_2014_01_003 crossref_primary_10_1080_14787210_2017_1279970 crossref_primary_10_1016_j_cll_2009_10_002 crossref_primary_10_1016_j_jcv_2011_10_002 crossref_primary_10_1128_CVI_00230_15 crossref_primary_10_1080_17476348_2025_2479611 crossref_primary_10_1099_vir_0_030049_0 crossref_primary_10_3390_v10090505 |
| Cites_doi | 10.1006/viro.1998.9242 10.1056/NEJMra022812 10.3201/eid1004.030393 10.1073/pnas.0503989102 10.1073/pnas.93.5.2186 10.1586/14760584.5.5.695 10.1016/S1473-3099(04)01058-8 10.1128/JVI.00318-06 10.1128/CMR.17.2.390-412.2004 10.1128/JCM.42.3.981-986.2004 10.1128/JVI.00736-06 10.1016/j.abb.2005.02.004 10.1128/JVI.78.24.14003-14011.2004 10.1128/JVI.79.14.8894-8903.2005 10.1111/j.1440-1754.2006.00825.x 10.1086/504262 10.1038/sj.bmt.1703849 10.1086/340518 10.1016/j.etp.2006.02.014 10.1021/bi000471y 10.1006/viro.1996.0459 10.1038/3293 10.1016/j.virol.2005.09.007 10.1016/j.vaccine.2005.04.027 10.1038/nsb1295-1075 10.1128/JVI.00844-06 10.1016/S0006-291X(03)00197-9 10.1016/S0005-2736(03)00164-0 10.1128/JVI.01243-06 10.1086/513204 10.1086/425013 10.1073/pnas.91.21.9770 10.1055/s-2007-976493 10.7326/0003-4819-144-5-200603070-00010 10.1086/344319 10.1111/j.1745-7254.2005.00193.x 10.3201/eid1006.031097 10.1038/89098 10.1093/protein/15.5.365 10.1016/S0168-1702(02)00256-3 10.1007/s10024-004-1011-2 10.1128/AAC.50.2.774-777.2006 10.1093/emboj/20.15.4024 10.1128/JVI.00106-07 10.1128/JVI.78.13.6927-6937.2004 10.1006/viro.2001.1355 10.1128/AAC.01598-05 |
| ContentType | Journal Article |
| Copyright | 2008 INIST-CNRS Copyright © 2008 American Society for Microbiology Copyright © 2008, American Society for Microbiology |
| Copyright_xml | – notice: 2008 INIST-CNRS – notice: Copyright © 2008 American Society for Microbiology – notice: Copyright © 2008, American Society for Microbiology |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T7 7U9 8FD C1K FR3 H94 P64 7X8 5PM |
| DOI | 10.1128/AAC.00793-07 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Industrial and Applied Microbiology Abstracts (Microbiology A) Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database AIDS and Cancer Research Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic Virology and AIDS Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology Biology |
| EISSN | 1098-6596 |
| EndPage | 287 |
| ExternalDocumentID | PMC2223880 0793-07 17967906 20210384 10_1128_AAC_00793_07 aac_52_1_279 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ IQODW CGR CUY CVF ECM EIF NPM - 08R 0R 55 A AAPBV ABFLS ADACO ADBIT AFMIJ BXI GJ HZ RHF ZA5 7T7 7U9 8FD C1K FR3 H94 P64 7X8 5PM |
| ID | FETCH-LOGICAL-a464t-28d543d5f5fb0bd253e58a3ddfc6fe879fe8672b6eda75edde8c6c1cf9555dd3 |
| ISSN | 0066-4804 |
| IngestDate | Thu Aug 21 13:47:23 EDT 2025 Fri Jul 11 09:09:35 EDT 2025 Thu Jul 10 23:57:01 EDT 2025 Tue Dec 28 13:59:20 EST 2021 Mon Jul 21 05:55:30 EDT 2025 Mon Jul 21 09:12:09 EDT 2025 Thu Apr 24 22:55:12 EDT 2025 Tue Jul 01 02:00:24 EDT 2025 Wed May 18 15:35:06 EDT 2016 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Human Metapneumovirus Evaluation Identification Efficiency Fusion inhibitor |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a464t-28d543d5f5fb0bd253e58a3ddfc6fe879fe8672b6eda75edde8c6c1cf9555dd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Corresponding author. Mailing address: CHUQ-CHUL, Room RC-709, 2705 Blvd Laurier, Quebec City, Quebec, Canada G1V 4G2. Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail: Guy.Boivin@crchul.ulaval.ca |
| PMID | 17967906 |
| PQID | 19988978 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | pubmed_primary_17967906 proquest_miscellaneous_19988978 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2223880 crossref_primary_10_1128_AAC_00793_07 pascalfrancis_primary_20210384 highwire_asm_aac_52_1_279 proquest_miscellaneous_70170787 asm2_journals_10_1128_AAC_00793_07 crossref_citationtrail_10_1128_AAC_00793_07 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-01-01 |
| PublicationDateYYYYMMDD | 2008-01-01 |
| PublicationDate_xml | – month: 01 year: 2008 text: 2008-01-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States |
| PublicationTitle | Antimicrobial Agents and Chemotherapy |
| PublicationTitleAbbrev | AAC |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2008 |
| Publisher | American Society for Microbiology American Society for Microbiology (ASM) |
| Publisher_xml | – name: American Society for Microbiology – name: American Society for Microbiology (ASM) |
| References | e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 e_1_3_2_41_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_50_2 (e_1_3_2_46_2) 2005; 436 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_19_2 (e_1_3_2_6_2) 1999 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 (e_1_3_2_35_2) 1999; 79 12402203 - J Infect Dis. 2002 Nov 1;186(9):1330-4 16364733 - Virology. 2006 Jan 5;344(1):30-7 10995236 - Biochemistry. 2000 Sep 26;39(38):11684-95 16873237 - J Virol. 2006 Aug;80(16):7799-806 16638630 - Exp Toxicol Pathol. 2006 Jun;57 Suppl 2:13-20 17522220 - J Virol. 2007 Aug;81(15):8315-24 12023774 - J Infect Dis. 2002 Jun 1;185(11):1660-3 17035305 - J Virol. 2007 Jan;81(1):141-9 15207075 - Emerg Infect Dis. 2004 Jun;10(6):1154-7 16174430 - Acta Pharmacol Sin. 2005 Oct;26(10):1165-73 16630317 - J Paediatr Child Health. 2006 Apr;42(4):174-8 16973588 - J Virol. 2006 Oct;80(19):9837-49 16723558 - Antimicrob Agents Chemother. 2006 Jun;50(6):2000-8 12033771 - Virology. 2002 Mar 30;295(1):119-32 15219553 - Lancet Infect Dis. 2004 Jul;4(7):426-36 8700906 - Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91 17181442 - Expert Rev Vaccines. 2006 Oct;5(5):695-706 17407031 - Clin Infect Dis. 2007 May 1;44(9):1152-8 7937889 - Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4 9705252 - Virology. 1998 Aug 15;248(1):20-34 15964978 - Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9288-93 12773651 - N Engl J Med. 2003 May 29;348(22):2228-38 12573494 - Virus Res. 2003 Feb;91(2):163-9 12621469 - Bone Marrow Transplant. 2003 Feb;31(4):309-10 15004041 - J Clin Microbiol. 2004 Mar;42(3):981-6 15084507 - Clin Microbiol Rev. 2004 Apr;17(2):390-412 16436743 - Antimicrob Agents Chemother. 2006 Feb;50(2):774-7 17458775 - Semin Respir Crit Care Med. 2007 Apr;28(2):213-21 15797244 - Arch Biochem Biophys. 2005 Apr 15;436(2):316-22 12615056 - Biochem Biophys Res Commun. 2003 Mar 14;302(3):469-75 11385510 - Nat Med. 2001 Jun;7(6):719-24 15547771 - Pediatr Dev Pathol. 2004 Sep-Oct;7(5):478-86; discussion 421 9809555 - Nat Med. 1998 Nov;4(11):1302-7 11483506 - EMBO J. 2001 Aug 1;20(15):4024-34 15529254 - J Infect Dis. 2004 Dec 1;190(11):1913-8 15927322 - Vaccine. 2005 Aug 22;23(36):4473-80 15200856 - Emerg Infect Dis. 2004 Apr;10(4):658-66 15194769 - J Virol. 2004 Jul;78(13):6927-37 8806544 - Virology. 1996 Sep 1;223(1):103-12 10576209 - Lab Invest. 1999 Nov;79(11):1385-92 12034856 - Protein Eng. 2002 May;15(5):365-71 15564507 - J Virol. 2004 Dec;78(24):14003-11 15994783 - J Virol. 2005 Jul;79(14):8894-903 16520475 - Ann Intern Med. 2006 Mar 7;144(5):344-9 17050599 - J Virol. 2007 Jan;81(2):698-707 8846219 - Nat Struct Biol. 1995 Dec;2(12):1075-82 16703506 - J Infect Dis. 2006 Jun 15;193(12):1634-42 12873767 - Biochim Biophys Acta. 2003 Jul 11;1614(1):73-84 |
| References_xml | – ident: e_1_3_2_18_2 doi: 10.1006/viro.1998.9242 – ident: e_1_3_2_19_2 doi: 10.1056/NEJMra022812 – ident: e_1_3_2_43_2 doi: 10.3201/eid1004.030393 – ident: e_1_3_2_50_2 doi: 10.1073/pnas.0503989102 – ident: e_1_3_2_23_2 doi: 10.1073/pnas.93.5.2186 – ident: e_1_3_2_7_2 doi: 10.1586/14760584.5.5.695 – ident: e_1_3_2_9_2 doi: 10.1016/S1473-3099(04)01058-8 – ident: e_1_3_2_40_2 doi: 10.1128/JVI.00318-06 – ident: e_1_3_2_13_2 doi: 10.1128/CMR.17.2.390-412.2004 – ident: e_1_3_2_28_2 doi: 10.1128/JCM.42.3.981-986.2004 – ident: e_1_3_2_34_2 doi: 10.1128/JVI.00736-06 – volume: 436 start-page: 316 year: 2005 ident: e_1_3_2_46_2 publication-title: Arch. Biochem. Biophys. doi: 10.1016/j.abb.2005.02.004 – ident: e_1_3_2_2_2 doi: 10.1128/JVI.78.24.14003-14011.2004 – ident: e_1_3_2_17_2 doi: 10.1128/JVI.79.14.8894-8903.2005 – start-page: 14 year: 1999 ident: e_1_3_2_6_2 publication-title: Introduction to protein structure – volume: 79 start-page: 1385 year: 1999 ident: e_1_3_2_35_2 publication-title: Lab. Investig. – ident: e_1_3_2_31_2 doi: 10.1111/j.1440-1754.2006.00825.x – ident: e_1_3_2_16_2 doi: 10.1086/504262 – ident: e_1_3_2_8_2 doi: 10.1038/sj.bmt.1703849 – ident: e_1_3_2_33_2 doi: 10.1086/340518 – ident: e_1_3_2_25_2 doi: 10.1016/j.etp.2006.02.014 – ident: e_1_3_2_24_2 doi: 10.1021/bi000471y – ident: e_1_3_2_49_2 doi: 10.1006/viro.1996.0459 – ident: e_1_3_2_20_2 doi: 10.1038/3293 – ident: e_1_3_2_22_2 doi: 10.1016/j.virol.2005.09.007 – ident: e_1_3_2_11_2 doi: 10.1016/j.vaccine.2005.04.027 – ident: e_1_3_2_26_2 doi: 10.1038/nsb1295-1075 – ident: e_1_3_2_10_2 doi: 10.1128/JVI.00844-06 – ident: e_1_3_2_45_2 doi: 10.1016/S0006-291X(03)00197-9 – ident: e_1_3_2_30_2 doi: 10.1016/S0005-2736(03)00164-0 – ident: e_1_3_2_29_2 doi: 10.1128/JVI.01243-06 – ident: e_1_3_2_4_2 doi: 10.1086/513204 – ident: e_1_3_2_27_2 doi: 10.1086/425013 – ident: e_1_3_2_47_2 doi: 10.1073/pnas.91.21.9770 – ident: e_1_3_2_12_2 doi: 10.1055/s-2007-976493 – ident: e_1_3_2_14_2 doi: 10.7326/0003-4819-144-5-200603070-00010 – ident: e_1_3_2_3_2 doi: 10.1086/344319 – ident: e_1_3_2_21_2 doi: 10.1111/j.1745-7254.2005.00193.x – ident: e_1_3_2_5_2 doi: 10.3201/eid1006.031097 – ident: e_1_3_2_42_2 doi: 10.1038/89098 – ident: e_1_3_2_39_2 doi: 10.1093/protein/15.5.365 – ident: e_1_3_2_32_2 doi: 10.1016/S0168-1702(02)00256-3 – ident: e_1_3_2_44_2 doi: 10.1007/s10024-004-1011-2 – ident: e_1_3_2_15_2 doi: 10.1128/AAC.50.2.774-777.2006 – ident: e_1_3_2_37_2 doi: 10.1093/emboj/20.15.4024 – ident: e_1_3_2_48_2 doi: 10.1128/JVI.00106-07 – ident: e_1_3_2_38_2 doi: 10.1128/JVI.78.13.6927-6937.2004 – ident: e_1_3_2_41_2 doi: 10.1006/viro.2001.1355 – ident: e_1_3_2_36_2 doi: 10.1128/AAC.01598-05 – reference: 12573494 - Virus Res. 2003 Feb;91(2):163-9 – reference: 11385510 - Nat Med. 2001 Jun;7(6):719-24 – reference: 15927322 - Vaccine. 2005 Aug 22;23(36):4473-80 – reference: 12023774 - J Infect Dis. 2002 Jun 1;185(11):1660-3 – reference: 7937889 - Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4 – reference: 15564507 - J Virol. 2004 Dec;78(24):14003-11 – reference: 16723558 - Antimicrob Agents Chemother. 2006 Jun;50(6):2000-8 – reference: 12033771 - Virology. 2002 Mar 30;295(1):119-32 – reference: 15207075 - Emerg Infect Dis. 2004 Jun;10(6):1154-7 – reference: 17181442 - Expert Rev Vaccines. 2006 Oct;5(5):695-706 – reference: 17035305 - J Virol. 2007 Jan;81(1):141-9 – reference: 17458775 - Semin Respir Crit Care Med. 2007 Apr;28(2):213-21 – reference: 12773651 - N Engl J Med. 2003 May 29;348(22):2228-38 – reference: 15219553 - Lancet Infect Dis. 2004 Jul;4(7):426-36 – reference: 16174430 - Acta Pharmacol Sin. 2005 Oct;26(10):1165-73 – reference: 16973588 - J Virol. 2006 Oct;80(19):9837-49 – reference: 15084507 - Clin Microbiol Rev. 2004 Apr;17(2):390-412 – reference: 16520475 - Ann Intern Med. 2006 Mar 7;144(5):344-9 – reference: 15964978 - Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9288-93 – reference: 16364733 - Virology. 2006 Jan 5;344(1):30-7 – reference: 8700906 - Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91 – reference: 12873767 - Biochim Biophys Acta. 2003 Jul 11;1614(1):73-84 – reference: 15004041 - J Clin Microbiol. 2004 Mar;42(3):981-6 – reference: 12615056 - Biochem Biophys Res Commun. 2003 Mar 14;302(3):469-75 – reference: 16703506 - J Infect Dis. 2006 Jun 15;193(12):1634-42 – reference: 11483506 - EMBO J. 2001 Aug 1;20(15):4024-34 – reference: 16638630 - Exp Toxicol Pathol. 2006 Jun;57 Suppl 2:13-20 – reference: 15194769 - J Virol. 2004 Jul;78(13):6927-37 – reference: 15547771 - Pediatr Dev Pathol. 2004 Sep-Oct;7(5):478-86; discussion 421 – reference: 15797244 - Arch Biochem Biophys. 2005 Apr 15;436(2):316-22 – reference: 15529254 - J Infect Dis. 2004 Dec 1;190(11):1913-8 – reference: 16873237 - J Virol. 2006 Aug;80(16):7799-806 – reference: 10576209 - Lab Invest. 1999 Nov;79(11):1385-92 – reference: 15200856 - Emerg Infect Dis. 2004 Apr;10(4):658-66 – reference: 8846219 - Nat Struct Biol. 1995 Dec;2(12):1075-82 – reference: 16630317 - J Paediatr Child Health. 2006 Apr;42(4):174-8 – reference: 8806544 - Virology. 1996 Sep 1;223(1):103-12 – reference: 15994783 - J Virol. 2005 Jul;79(14):8894-903 – reference: 9705252 - Virology. 1998 Aug 15;248(1):20-34 – reference: 17522220 - J Virol. 2007 Aug;81(15):8315-24 – reference: 12621469 - Bone Marrow Transplant. 2003 Feb;31(4):309-10 – reference: 9809555 - Nat Med. 1998 Nov;4(11):1302-7 – reference: 12402203 - J Infect Dis. 2002 Nov 1;186(9):1330-4 – reference: 10995236 - Biochemistry. 2000 Sep 26;39(38):11684-95 – reference: 16436743 - Antimicrob Agents Chemother. 2006 Feb;50(2):774-7 – reference: 17407031 - Clin Infect Dis. 2007 May 1;44(9):1152-8 – reference: 17050599 - J Virol. 2007 Jan;81(2):698-707 – reference: 12034856 - Protein Eng. 2002 May;15(5):365-71 |
| SSID | ssj0006590 |
| Score | 2.1243076 |
| Snippet | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit... Human metapneumovirus (hMPV) can cause acute upper and lower respiratory tract infections that are particularly severe in young children, elderly subjects, and... |
| SourceID | pubmedcentral proquest asm2 pubmed pascalfrancis crossref highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 279 |
| SubjectTerms | Amino Acid Sequence Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral Agents Antiviral Agents - chemistry Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Biological and medical sciences Cell Line Cell Line, Tumor Escherichia coli Female Human immunodeficiency virus Human metapneumovirus Human respiratory syncytial virus Humans Inhibitory Concentration 50 Medical sciences Membrane Fusion Membrane Fusion - drug effects Metapneumovirus Metapneumovirus - drug effects Metapneumovirus - pathogenicity Mice Mice, Inbred BALB C Molecular Sequence Data Parainfluenza virus Paramyxoviridae Infections Paramyxoviridae Infections - drug therapy Paramyxoviridae Infections - virology Peptides Peptides - chemistry Peptides - pharmacology Peptides - therapeutic use Pharmacology. Drug treatments Viral Fusion Proteins Viral Fusion Proteins - chemistry |
| Title | Identification and Evaluation of a Highly Effective Fusion Inhibitor for Human Metapneumovirus |
| URI | http://aac.asm.org/content/52/1/279.abstract https://www.ncbi.nlm.nih.gov/pubmed/17967906 https://journals.asm.org/doi/10.1128/AAC.00793-07 https://www.proquest.com/docview/19988978 https://www.proquest.com/docview/70170787 https://pubmed.ncbi.nlm.nih.gov/PMC2223880 |
| Volume | 52 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIhAXBMsrPBYLwV7YLG0SO86x6i4UUFEPRdoTkePYNFLTVm1aqfvrGcdOmna3EnCJqsR1U83nx4zn-wah96FKhE8Zdzu-DN1AceKyhEi3nQglpJJeRDQ5efCD9n8G367IVat13WSXFMm5uL6VV_I_VoV7YFfNkv0Hy9adwg34DPaFK1gYrn9lY8OyVTbsVp4DbNW7DfNRyxFPNjZto5T4Xi1NeuM4S2A0L8o8Q1OpL5cFn0_lKp-ts4UNCNQ6y0WWZ6VokxYX-F3y4kpK3FjmlsRVB-cvNDuML20RgJ45i580DvD7PJe2UPxA--ru5bp-NtTRf9mgzzSirbNsbb71ZbXZCVewRrjCTsGUugEzNYerKZh4N6Bm51NTaebmPO9p7kK329PS5zoDMWw2AyvN89LmMN3QMGrviW0b78c-uoPueuBi6OoXF1-_16s4JSY-V71uRZrw2Kfmz2rRWdsRLOp8mXu7G5xKdFrn3PIlDDtl6qXc5tDs5-U2NjqjR-ih9VBw18DtMWrJ6TG6Z2qWbo7R_YHNxjhGp0Oje745w6MtjW95hk_xcKuIvnmCfu0CFQNw8BaoeKYwxwaouAYqNkDFNVAxABWXQMV7QH2KRp8vR72-awt7uDygQeF6LCWBnxJFVNJOUo_4kjDup6kSVEkWRnChoZdQmfKQSFiBmaCiI1RECElT_xk6ms6m8gXCIumkbaqU8MHt94MooZzDdisNOzDhBIQ76J22SWwH7TIufV6PxWDDuLRh3A4d9LGyWCysMr4u0DI50PpD3XpuFGEOtHMq48fwDjHnIiZe3IkB0w462UFD3ZGnQzA-Cxz0toJHDPO9PsTjUzlbwR-IIsaikB1uEWpJLFiHHfTcwGn7mhapDgp3gFY30Frzu0-m2bjUnNduBCz1Lw_2-Qo92A731-ioWKzkG9ivF8lJObD-ANwM7dM |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+and+evaluation+of+a+highly+effective+fusion+inhibitor+for+human+metapneumovirus&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Deffrasnes%2C+C%C3%A9line&rft.au=Hamelin%2C+Marie-Eve&rft.au=Prince%2C+Gregory+A&rft.au=Boivin%2C+Guy&rft.date=2008-01-01&rft.issn=0066-4804&rft.volume=52&rft.issue=1&rft.spage=279&rft_id=info:doi/10.1128%2FAAC.00793-07&rft_id=info%3Apmid%2F17967906&rft.externalDocID=17967906 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |